Lamprell Laura, Broadhurst Matthew
Queensland Centre for Otolaryngology and Voice, Level 7, 457 Wickham Terrace, Spring Hill, QLD 4000, Australia.
Queensland Centre for Otolaryngology and Voice, Level 7, 457 Wickham Terrace, Spring Hill, QLD 4000, Australia.
J Voice. 2023 Oct 11. doi: 10.1016/j.jvoice.2023.08.020.
To present three case reports of cryptococcal laryngitis managed with potassium-titanyl-phosphate (KTP) laser, where only one case managed with KTP laser has previously been published to date to our knowledge. Further, to systematically review the medical literature and describe the epidemiology, clinical assessment, treatment, and prognosis of laryngeal cryptococcosis.
The PubMed, Embase, and OVID MEDLINE databases were searched using the terms "cryptococcal laryngitis" or "cryptococcus" and "larynx or laryngeal."
Thirty-eight cases were identified. The median age was 65 years with a 1 male:1.2 female ratio. Thirty-six cases (95%) presented with hoarseness. Twenty-one cases (55%) were systemically immunosuppressed and 19 (50%) were taking an inhaled corticosteroid. This paper lists the five clinical features (i. white exudate or lesion; ii. exophytic, verrucous or tumor-like mass; iii. diffuse erythema; iv. mucosal irregularity; v. thickened vocal fold) and four pathologic features or tests (i. Grocott Gomori Methenamine stain; ii. Mucicarmine stain; iii. fungal or yeast organisms; iv. fungal culture) that encompass 97% of cases of cryptococcal laryngitis reported in the medical literature. In 34 cases (89%), antifungal therapy was given. Four cases (11%) had excisional biopsy and 11 (29%) received combined surgery and medical therapy. There was uncomplicated resolution in 24 cases (63%).
Cryptococcal laryngitis is a rare cause of hoarseness that may be mistaken for malignancy or may be a manifestation of disseminated cryptococcal infection or underlying immunosuppression. Clinicians should be aware of the diagnostic features of cryptococcal laryngitis to facilitate diagnosis and treatment to prevent complicated disease and overly aggressive treatment.
报告三例采用磷酸钛氧钾(KTP)激光治疗的隐球菌性喉炎病例,据我们所知,迄今为止仅有一例采用KTP激光治疗的病例被发表。此外,系统回顾医学文献,描述喉隐球菌病的流行病学、临床评估、治疗及预后。
使用“隐球菌性喉炎”或“隐球菌”以及“喉或喉部”等术语检索PubMed、Embase和OVID MEDLINE数据库。
共确定38例病例。中位年龄为65岁,男女比例为1:1.2。36例(95%)表现为声音嘶哑。21例(55%)存在全身免疫抑制,19例(50%)正在使用吸入性糖皮质激素。本文列出了涵盖医学文献中报道的97%的隐球菌性喉炎病例的五个临床特征(i.白色渗出物或病变;ii.外生性、疣状或肿瘤样肿块;iii.弥漫性红斑;iv.黏膜不规则;v.声带增厚)和四个病理特征或检查(i.格罗科特·戈莫里六胺银染色;ii.黏液卡红染色;iii.真菌或酵母生物体;iv.真菌培养)。34例(89%)接受了抗真菌治疗。4例(11%)进行了切除活检,11例(29%)接受了手术与药物联合治疗。24例(63%)病情顺利缓解。
隐球菌性喉炎是声音嘶哑的罕见病因,可能被误诊为恶性肿瘤,也可能是播散性隐球菌感染或潜在免疫抑制的表现。临床医生应了解隐球菌性喉炎的诊断特征,以便于诊断和治疗,预防疾病复杂化及过度积极治疗。